In 1993, Zolpidem (Ambien ® ), a non-benzodiazepine hypnotic agent, was approved for use in the United States for the short-term treatment of insomnia. Zolpidem has a rapid onset of action and short elimination half-life, rendering it ideal as a sleep aid. The objective of this study was to evaluate, and retrospectively compare, the use of the Immunalysis ® ELISA kit and gas chromatograpy-mass spectrometry (GC-MS) to screen blood/urine specimens for zolpidem. In addition, results for the incidence of zolpidem in suspected DUI drivers in 2007 are compared to previous years' data. The ELISA kit was evaluated for cross-reactivity with zaleplon and zopiclone and zolpidem metabolite I. Urine samples (n = 100) and blood samples (n = 100) were selected from specimens received into the DUI laboratory in 2007 and were screened via the Immunalysis Zolpidem ELISA kit and on GC-MS in full EI scan mode following an alkaline liquid-liquid extraction. Results show 5% of the urine and blood samples screened positive for zolpidem using the ELISA kits, and all 5% confirmed positive for zolpidem using GC-MS. The ELISA kit demonstrated no cross-reactivity to zaleplon or zopiclone at a spiked urine concentration of 1000 ng/mL. Ten cases of suspected DUI drivers in 2007 confirmed positive for zolpidem by ELISA and GC-MS in blood/urine, a higher incidence rate than in the previous years. Because of the low percentage elimination of the parent compound in urine, a screening method for the detection of the main metabolite of zolpidem may be needed for better detection of drug impairment driving due to zolpidem.
Introduction
It is reported that approximately 35% of the population suffers from insomnia at some point in their lives (1) , with the majority of patients using prescribed medication. In 1993, zolpidem (Ambien ® ), a nonbenzodiazepine hypnotic agent, was approved for use in the United States for the short-term treatment of insomnia. Zolpidem, a Schedule IV controlled substance under the Federal Controlled Substance Act, has a rapid onset of action and short elimination half-life, rendering it ideal as a sleep aid. In response to the increasing use of sleeping medication in the U.S., with zolpidem prescription rates increasing from 18 million to 28 million between 2001 and 2006 (1) , it is necessary to have a quick and reliable method for the screening of biological samples for zolpidem and metabolites. Given the specific role of zolpidem as a sleep inducer and the reported adverse side effects including somnolence (sleepiness), sleepwalking, and amnesia (1, 2) , it is reasonable to assume that zolpidem may have a role in drugimpaired driving investigations. Zolpidem has also been shown to impair coordination, reactive, and cognitive skills (3) and to reduce motor skills (4) . Several studies have implicated zolpidem as causing residual and adverse effects on an individual for up to 7 h post-dose (5) (6) (7) . Some patients may not devote a full 8 h to sleep after taking zolpidem. Typical cases include dosing in the middle of the night or dosing after failing to fall asleep. A study in which patients were dosed (10 mg) in the middle of the night demonstrated that individuals showed significant impairment when driving, comparable to a blood alcohol concentration of 0.08 g/dL, when time was approximately 7 h from dosing to driving (8) . It has been shown that zolpidem has an additive impairment effect on driving when used in combination with alcohol and other central nervous system depressants (9, 10) . This renders zolpidem, either when taken alone or in combination with other drugs, capable of causing/contributing to drug-impaired driving (DUI). Many of the alleged sleep-driving cases have involved substantial use of alcohol.
Zolpidem undergoes extensive metabolism by oxidation and hydroxylation via a variety of cytochrome P450 enzymes that results in less than 1% of the parent drug being excreted in the urine (11) . Metabolite studies of zolpidem in humans have demonstrated at least six metabolites (12) . The phenyl carboxylic acid metabolite (I) predominates at 51% of the excreted dose. None of the metabolites have been shown to be pharmacologically active (11) .
A review published in 2005 by Rohrig and Moore (13) discussed a variety of analytical techniques that were used to detect zolpidem in biological specimens. Gas or liquid chromatography coupled to mass spectrometry (GC and LC-MS) based screening methodologies are the most commonly employed analysis of zolpidem in forensic laboratories. A two-step testing strategy, each based on a different underlying principle, is required for the identification of a drug to meet forensically accepted criteria. A review of the literature identified a lack of publications on the use of enzyme-linked immunosorbent assay (ELISA) to screen for Zolpidem in blood and urine specimens. Piegies et al. published an article on the cross-reactivity of zolpidem with then currently available immunoassay drug screens and concluded that zolpidem does not cross react with benzodiazepines, cocaine, opiate, barbiturate, cannabinoids, or amphetamines assay from Abbott ADx or Syva EMIT II (14) . A microplate enzyme-linked immunosorbent assay was launched in 1994 by Immunalysis. This paper presents an evaluation of this zolpidem kit from Immunalysis (Pomona, CA) using both blood and urine case specimens. The new ELISA Zolpidem assay technology enhanced our existing approach for the presumptive testing of blood and urine by immunoassay, ELISA, and GC-MS full scan qualitative analysis for drugs. Results from the specimens tested by the Immunalysis Zolpidem assay were compared to previous collected results from an alkaline drug screen by GC-MS. The results of a cross-reactivity study are presented from testing two similar, commonly prescribed nonbenzodiazepine hypnotic compounds, zaleplon and zopiclone, and the main zolpidem metabolite I (Figure 1 ). Finally, all results on blood and urine cases over the last six years are evaluated to document any trends in zolpidem use in suspected DUI drivers.
Experimental Apparatus
ELISA plate washer (Tecan, Tecan Group Ltd., Männedorf, Switzerland) and reader (TecanSpectra II) were kindly loaned to the University of Miami Forensic Toxicology Laboratory by Immunalysis.
GC-MS analysis was preformed on an Agilent 5890 series II GC interfaced to a 5972 mass selective detector operated in electron impact mode. The electron multiplier was set 200 volts relative to the autotune value. The GC was fitted with a Restek RXi-5MS column (30 m × 0.32-mm i.d × 0.25-µm d.f.) operated in splitless mode (bottom gooseneck liner with no glass wool) with helium as the carrier gas at 1 mL/min and an injection volume of 2 µL. The injector and detector temperatures were 270°C and 300°C, respectively. The initial oven temperature was held at 70°C for 2 min, then ramped at 13ºC/min to 230°C with no hold time, and then ramped at 12ºC/min to 300°C at a final hold of 5 min. The MS was operated in the full scan mode (42-550 amu) and data was acquired and analyzed with Agilent Chemstation software version G1701AA (Santa Clara, CA).
Materials

Reagents and supplies
All reagents were J.T. Baker (Phillipsburg, NJ) reagent grade, and solvents, except for acetonitrile (Pierce Chemical, Rockford, IL) were Fisher (Thermo Fisher Scientific, Waltham, MA) HPLC-grade or equivalent.
Zolpidem ELISA ® kits were kindly donated by Immunalysis. The kit included plates, phosphate buffer, zolpidem conjugate, positive reference standard, synthetic negative urine, zolpidem TMB substrate, and an acid stop solution.
Standards and controls
Individual certified stock solutions of prazepam, zolpidem (at 1 mg/mL in methanol) were purchased from Cerilliant (Round Rock, TX). Zaleplon, ethylmorphine, and n-propylamphetamine (at 1 mg/mL in methanol) were purchased from Alltech-Applied Science Labs (State College, PA). Zopiclone was also purchased from Alltech at 1 mg/mL concentration in acetonitrile. Cyclizine was obtained in powder form from SigmaAldrich (St. Louis, MO) and prepared in methanol at a 1 mg/mL solution, and this stock standard was stored at -20°C when not in use.
Zolpidem metabolite SL84.0589-10 (Synthelabo Recherche, France), metabolite I, was kindly donated by the Federal Bureau of Investigation toxicology laboratory (Quantico, VA) and was prepared in methanol at a concentration of 1 mg/mL. Liquicheck™ external quality controls (QC) were purchased from Bio-Rad laboratories (Irvine, CA), containing a mixture of 17 drugs at two different concentration levels.
A working internal standard mixture comprising four drugs, n-propylamphetamine, cyclizine, ethylmorphine, and prazepam at a concentration of 10 ng/µL was prepared in methanol by the dilution of stock 1 mg/mL standards. All standard solutions were stored at -20°C when not in use.
Negative urine was prepared in-house by collection of urine from a non-drug taking volunteer and evaluated by GC-MS and current immunoassay panel (amphetamines, barbiturates, benzodiazepines, cocaine/metabolite, opiates, and cannabinoids) to ensure the absence of drugs. Certified negative blood was purchased from Quality Assurance Services (Augusta, GA). For the ELISA assay, negative blood was collected from a nondrug-taking volunteer into 10-cc grey stopper vacutainer (GSV) tubes containing fluoride and oxalate as used by law enforcement agencies to submit case specimens. This blood was certified as negative for zolpidem and other alkaline drugs by GC-MS and by an ELISA panel (Venture Labs, Redwood City, CA) testing for amphetamine; methamphetamine; barbiturates; cannabinoids; opiate; oxycodone; and cocaine.
Specimens
One hundred urine (unpreserved) and 100 blood samples (GSV) were randomly selected from suspected DUI specimens submitted to the Forensic Toxicology laboratory for drug and alcohol analyses in 2007. Specimens were randomly selected from each month to gain a representative sample across the year. The urine specimens had previously been screened by immunoassay (Microgenics, Fremont, CA) for marijuana, amphetamines, barbiturates, cocaine, opiates, and benzodiazepines, and blood screened by an 8 drug panel ELISA (Venture Labs) including the aforementioned drugs as well as oxycodone. An alkaline drug screen by GC-MS (method documented below) was carried out on all specimens to screen for an extensive range of drugs. A specimen with positive screening was subjected to confirmatory drug analysis via GC-MS as required.
Methods
ELISA
The ELISA method was carried out in accordance with the manufacturer's package insert (15) . Briefly, urine and blood specimens were prepared by diluting 1:10 with kit-supplied phosphate buffer (pH 7) on the day of analyses. Calibrators and controls were set up in accordance with Table I and were treated identically to specimens. To each appropriate well, 50 µL of diluted blood or 25 µL of diluted urine, calibrator, or control were added. All calibrators and controls were performed in duplicate with the placement of a negative and positive control every 10 samples. Next, 100 µL of enzyme was added and then incubated for 60 min in the dark (because of reagent sensitivity to light). After incubation, the plate was washed six times with deionized water and dried using the Tecan plate washer. A chromomeric substance (Zolpidem TMB) was added, and the plate then incubated for an additional 30 min in the dark (due to reagent sensitivity to light). The reaction was stopped with a dilute acid, and the plate read at 450 nm. The yellow color intensity produced from the drug binding was inversely proportional to the amount of zolpidem in the specimen. Data reduction was accomplished using the supplied Magellan software (Immunalysis). A cut-off value of 25 ng/mL of zolpidem was used for urine with a positive control set at twice the cutoff, and a low control of 12.5 ng/mL. For blood specimens, a cut-off value of 10 ng/mL, a positive control at 20 ng/mL, and a low control of 5 ng/mL were chosen. The absorbance of the specimen well was compared to the mean absorbance of the cut-off wells, and if the specimen absorbance was equal or lower than the cut-off absorbance the sample was reported as presumptive positive. If the specimen absorbance was higher than the cut-off well, then the sample was reported as negative.
Method validation for ELISA
Accuracy, precision, and cross-reactivity studies were reported by Immunalysis (15) . Additional intra-assay (intraplate) precision was determined using a fortified zolpidem urine control at 40 ng/mL, one positive, and one negative specimen (determined by GC-MS) all analyzed five times in the same assay. Immunalysis provided information on cross-reactivity studies using a wide variety of drugs (15) . However, this list did not include zaleplon, zopiclone, or zolpidem main metabolite I (Figure 2) . The cross-reactivity of the assay was assessed by fortifying negative urine at concentrations of 1000, 100, and 50 ng/mL of each compound and then subsequent analyses by ELISA.
GC-MS analysis
GC-MS screening for drugs was conducted with the alkaline liquid-liquid drug extraction with modifications to the published procedure of Forester et al. (16) . Briefly, urine and blood aliquots (2 mL) were dispensed into 17 mL silianized screw cap tubes. The internal standards were added to each tube of urine and blood to give a final concentration of 1000 ng/mL and 250 ng/mL, respectively. To each tube, 9 mL of n-butyl chloride/methylene chloride (9:1) was added and briefly vortex mixed. One milliliter of concentrated ammonium hydroxide (33%) was added, and the tube sealed with a Teflon lined cap. The samples were then extracted on a rotor rack for 15 min. Tubes were centrifuged at 3800 rpm for 5 min at -10°C and the organic layer transferred to a silianized conical tube and evaporated to just dryness in a TurboVap ® at 50°C under a stream of nitrogen. The dry urine extract was reconstituted with 50 µL iso-octane/Me 2 Cl 2 /ETOH (7:2:1); transferred to limited volume auto liquid sample vials; and analyzed via GC-MS in full scan mode. Blood extracts were reconstituted with 65 µL of silation grade acetonitrile and vortex mixed. The extract was then washed briefly by the addition of 500 µL of hexane (saturated with acetonitrile) and then centrifuged at 3800 rpm for 2 min at -10°C. The hexane was then aspirated to waste, and the acetonitrile transferred to limited volume ALS vials; and specimens analyzed by GC-MS in full scan mode.
Drugs, including zolpidem, were identified by Chemstation library search routines through the comparison of full scan mass spectra of an unknown to the stored full scan mass spectra generated from in-house certified standards. The inhouse library was used in conjunction with professionally available mass spectral libraries (American Academy of Forensic Sciences and Pfleger Maurer Weber) for drug identification. The retention time was within ± 2% of the 100 ng/mL standard for positive identification. If necessary, zolpidem was identified by performing an extracted ion chromatogram using m/z 235, 307, and 219 displayed in merged ion format (Figure 3 ). Identification criteria included retention time, relative ion abundances, acceptable chromatography, and a signal-to-noise ratio of greater than three.
To determine the urine assay limit of detection (LOD) for zolpidem using this extraction method with GC-MS in scan mode, negative urine was fortified with zolpidem at concentrations of 100, 80, 40, 20, 10, and 5 ng/mL, extracted by the previously mentioned method, and analyzed by GC-MS. The LOD was determined using the criteria cited previously.
Incidence study
All case results from the past six years were reviewed; all positive screened zolpidem cases by GC-MS were recorded and used to compare the occurrence of zolpidem in suspected DUI drivers in Miami-Dade County over a six-year period.
Results and Discussion
The study addressed several analytical parameters of the ELISA kit that had to be tested prior to case sample analysis. absorbance values for the controls across different plates with different lot numbers. In accordance with the Immunalysis protocol (15), a dose-response curve, or at least a positive cutoff calibrator, should be run with each assay plate (15) . Synthetic drug free urine intra-assay precision has been reported by the manufacturer (15) . "Real" positive and negative case urine samples were used in this study to examine intra assay precision with a case sample matrix. The in-house intraassay precision was determined using a fortified in-house negative urine sample at 40 ng/mL, and one positive and one negative urine specimen analyzed five times on the same plate (Table III) . The reproducibility of the absorbance values was consistent within ± 2 standard deviation, across the five replicates of the same sample. Zaleplon or zopiclone demonstrated no cross-reactivity at a concentration of 1000 ng/mL. The main zolpidem metabolite (I) failed to demonstrate cross-reactivity to the ELISA zolpidem assay at a concentration of 1000 ng/mL. This result implies that all the positive results obtained via the ELISA were due to the presence of the parent drug and not the main metabolite.
The performance of the ELISA kit was investigated by testing 200 (100 blood and 100 urine specimens) cases. Samples were previously analyzed by GC-MS and the ELISA results were compared to this GC-MS data of this study. The investigation into the LOD for the GC-MS method determined that at urine concentration of 10 ng/mL and higher, zolpidem could be identified using full scan GC-electron impact ionization-MS.
From the 100 urine specimens tested, five were presumptive positive for zolpidem using the ELISA kits (5%). A presumptive positive result corresponded to the specimen reading an absorbance equal to, or less than the absorbance of the zolpidem 25 ng/mL positive cut-off. In specimens where the absorbance was higher than the 25 ng/mL absorbance value, the result was reported as negative.
Comparison of the results with the GC-MS data demonstrated a 100% correlation between the ELISA and the GC-MS screen.
It is well recognized that zolpidem can cause impairment of motor driving skills up to 7 h after ingestion of a 10-mg dose, but research suggested that the potential for driving impairment may extend through to the following day, depending on interperson variability (19) . Villian et al. (20) analyzed urine specimens by LC-MS-MS with an LOD of 2 ng/mL from three volunteers. Urine was collected every 12 h after a 10-mg dose, with the first sample collected at 12 h. Results indicated that zolpidem could be detected for 60 h after dosing (20) . The three urine samples from the Villain study had a concentration range of 5-25 ng/mL, indicating wide variability in zolpidem concentration in the first urine collected post-dose (12 h). The excretion profiles of zolpidem in these three subjects also varied extensively over time and the main zolpidem metabolite was not measured (20) . An independent study by Lewis et al. reported that the first urine collected after a 10 mg dose at 8 h contained no zolpidem in the urine (21) , no LOD was reported for the "standard drug screen" used. This study progresses to investigate the ability to detect the main carboxylic acid metabolite of zolpidem with results demonstrating that the metabolite may serve as a better marker for recent zolpidem exposure in urine. These two studies should be viewed with caution, as they are very limited in sample size; however, they do give some indication of the high person-person variability. Studies have shown that driving may be impaired when dosed during the night and driving within 7 h (5-8); there is, however, limited literature on the urinary excretion profiles of zolpidem during this time period. This information would be useful when establishing screening cut-offs and ascertaining required detection limits for zolpidem in urine in DUI cases. Currently, the reported GC-MS full scan method has an LOD of 10 ng/mL for zolpidem in urine, and the ELISA detection cut-off limit is set at 25 ng/mL. From the previously mentioned case studies, these levels may not be adequate when trying to assess recent zolpidem use in suspected DUI drivers. From the 100 blood samples analyzed, the results showed that 5 out of the 100 specimens (5%) screened positive for zolpidem using the ELISA kit. A positive result corresponded to a specimen displaying absorbance values equal to, or less than, the absorbance measured in the 10 ng/mL positive cutoff control. However, four samples recorded absorbance values between the low positive control (5 ng/mL) and the cut-off (10 ng/mL). This indicated that these specimens may contain zolpidem, but in concentrations lower than the positive cut-off. Retrospective review of these case histories ascertained that all four cases had alcohol levels above 0.15 g/dL, and consequently, because of laboratory protocol, a drug screen was not carried out on these specimens.
Zolpidem has a half-life between 1.4 to 2 h, and studies showed that following a 10-mg dose, typical plasma levels were approximately 50 ng/mL at 5 h post-dose; consequently, zolpidem concentrations stay above the implemented 10 ng/mL screening cut-off for longer than 8 h (22) . As a result, one could determine that this concentration is appropriate to screen for zolpidem in blood for DUI cases.
Prior to 2008, all screening for zolpidem was conducted by full scan GC-MS. Two hundred blood/urine case samples randomly selected from suspected DUI drivers' cases in 2007 were subjected to ELISA and GC-MS analysis. Five urines and five bloods screened positive for zolpidem by ELISA and were confirmed positive by GC-MS, a higher incidence rate than in previous years (Figure 3) . The results of this review indicated a general upward trend in the identification of zolpidem in suspected DUI drivers that correlated with the increase in filled prescription for the period 2000-2006 (1). Table IV gives details on poly-drug use and some case demographics of all the cases confirming the involvement of zolpidem. It can be noted that a wide variety of substances are used concurrently with zolpidem. The most common drugs to be encountered with a positive zolpidem result were antidepressants, closely followed by benzodiazepines. The combination of anti-depressants and zolpidem is expected (12 cases) because of the large number of cases of depressed patients finding it difficult to sleep and requiring the coadministration of these drugs. Only 27% of zolpidem-positive cases involving DUI drivers were female. Of the seven blood-positive cases, only two had alcohol levels, and these were less than the legal driving limit (0.08 g/dL), so consequently all samples underwent a basic drug screen. Because of laboratory protocols, blood that was positive for ethanol at a level greater than 0.10 g/dL was not screened for drugs unless requested by law enforcement personnel. A further study that screens all positive alcohol blood samples for zolpidem would be of interest to determine the concurrent use of zolpidem and alcohol in DUI drivers, because many of the alleged sleep-driving cases have historically shown concurrent use of alcohol and zolpidem.
Conclusions
ELISA is an easy and high throughput technique that requires minimal sample volume and preparation and allows the rapid reporting of preliminary results. All samples that screened positive by ELISA confirmed positive for zolpidem in both blood and urine by GC-MS.
Because of inadequate excretion studies and the low concentration at which zolpidem is found in urine, zolpidem may not be the best target compound to determine recent exposure to zolpidem in urine. This kit was not useful for screening urine for the main zolpidem metabolite nor cross-reacted with zaleplon or zopiclone. GC-MS methods must address the screening for, and the identification of, zolpidem metabolites in biological specimens using acceptable sensitivity. Ideally, the combination of all three "Z" drugs and the main metabolites would be beneficial in immunoassay for the rapid screening of the non-benzodiazepine hypnotics.
Overall, the use of both ELISA and GC-MS techniques concurrently provided a two-step testing procedure with different underlying procedures that can be used to confirm the presence of zolpidem in a blood sample. It can be concluded that using a 10 ng/mL cut-off in blood will allow the confirmation of zolpidem exposure post 8 h of dosing and less, and this level should be appropriate for assessing driving impairment due to zolpidem. The study indicated an increase in the prevalence of zolpidem in DUI drivers in Miami, Florida, with 5% of the cases analyzed in this study identifying zolpidem in blood or urine. The drug can be found in isolation or present as a co-administration with other drugs, most typically antidepressants.
